Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of doxorubicin plus estramustine in
treating patients with metastatic recurrent prostate cancer that does not respond to hormone
therapy.